CTLA4 and neoplasm: Moreover, this therapy was safe and controllable toxicities.[159] G47Δ, a third‐generation oncolytic HSV‐1, was used in combination with anti‐CTLA4, and findings showed that antitumor responses were improved via recruitment of effector T cells into the TME and decreasing the frequency of Tregs at the tumor site.